AbbVie announced it has reached a voluntary, three-year agreement with the Trump administration aimed at expanding access to medicines and lowering costs for Americans, while the company commits to a decade-long investment push in U.S. research, development, and manufacturing.
Under the arrangement, AbbVie said it will offer low prices in Medicaid and broaden direct-to-patient options for several widely used treatments through a program it called TrumpRx. AbbVie said the expanded offerings will include medicines used by millions of Americans, naming ALPHAGAN, COMBIGAN, HUMIRA, and SYNTHROID among the products included.
In exchange, AbbVie said the administration will provide the company with an exemption from tariffs and protection from future pricing mandates during the term of the agreement. AbbVie said additional terms remain confidential.
Alongside the pricing and access commitments, AbbVie said it will invest $100 billion in the United States over the next decade, spanning research and development as well as capital investments such as manufacturing. The company framed the investment pledge as a measure intended to reinforce domestic pharmaceutical innovation and production.
AbbVie said the agreement aligns with what it described as the administration’s drug-pricing priorities, while also reflecting the government’s efforts to push for “global prices” that better reflect U.S.-based innovation. The company did not disclose specific implementation details, timelines for the direct-to-patient expansion, or the precise mechanics of the Medicaid pricing provisions.
AbbVie, which employs roughly 29,000 people in the U.S., said its medicines are used to treat about 16 million Americans each year and that it operates across therapeutic areas including immunology, oncology, neuroscience, and eye care, as well as its Allergan Aesthetics portfolio.
KEY QUOTE:
“AbbVie’s mission is to make a remarkable impact for the patients we serve around the world through our innovative medicines. With approximately 29,000 U.S.-based employees and products treating 16 million Americans annually, we understand the complexity and access challenges in our healthcare system. AbbVie is following President Trump’s call to action by reaching this agreement, allowing us to collectively move beyond policies that harm American innovation. Thank you to President Trump and his team for their leadership to help deliver cost savings and supporting our efforts to deliver innovative treatments for American patients.”
Robert A. Michael, Chairman and Chief Executive Officer, AbbVie
